Boston Scientific to Acquire Penumbra for $14.5 Billion to Reclaim Leadership in Neurovascular Intervention
Penumbra
Developer of Treatment Devices for Stroke and Other Neurovascular Diseases
Johnson & Johnson
Medical Device R&D and Manufacturer
Medtronic
Medical Device Manufacturer
January 15,Boston ScientificAnnounce with$14.5 billionAcquisition of Medical Technology CompaniesPenumbra, this is itsThe Second Largest Acquisition in Company History, marking the first medical device industry acquisition deal exceeding 10 billion US dollars in 2026.
According to the official announcement, Boston Scientific will complete the acquisition through a combination of cash and stock, with a per-share consideration of $374, of which 73% will be paid in cash and 27% in Boston Scientific common stock (each share can be exchanged for 3.8721 shares of Boston Scientific stock), representing a premium over Penumbra's last closing price.Premium of 19.3%, demonstrating Boston Scientific's determination to acquire. The deal is expected to be completed by mid-2026.
The core logic of this acquisition lies in the current business layout of Boston Scientific and Penumbra.High Complementarity, and behind this complementarity isBoston Scientific's Precise Strategic Layout Targeting Johnson & Johnson and Medtronic's Competitive Weaknesses。
This is Boston ScientificThe Second M&A Move This YearOn January 12, Boston Scientific announced the acquisitionValencia, expanding the urology product portfolio. As just concluded at the JPM conferenceBoston Scientific CEO Michael MahoneyAs mentioned, mergers and acquisitions in 2026 are the focus of Boston Scientific. If this acquisition is successfully completed, Boston Scientific will regain its leading position in the neurovascular field. Interestingly, the company had sold this related business to Stryker for $1.5 billion 15 years ago.
From the recently concluded JPM,Medtronic、Zimmer Biomet、StrykerBoth expressed anticipation for mergers and acquisitions. By 2026, it is a certainty that the medical device industry will enter a major M&A cycle. What is worth追问的是,Why Does Boston Scientific Want to Reclaim a Business It Sold 15 Years Ago?
According to industry insiders: First, the $14.5 billion acquisition of Penumbra is Boston Scientific's largest M&A deal in nearly 20 years, which...Directly Entering the "Must-Compete Track" of High-Growth Mechanical Thrombectomy and Neurovascular Intervention, the situation has changed significantly compared to 15 years ago; secondly, most of Boston Scientific's growth points and future pipelines come from in-depth development after acquisitions, such as Watchman, which came from the $575 million acquisition of Atritech in 2011; thirdly,The focus is on ecological construction and product closed-loop.In recent years, Medtronic has been actively acquiring companies such as Farapulse (PFA), Baylis (transseptal puncture), Preventice (remote ECG monitoring), and Axonics (neuromodulation), with a focus on technically mature and highly synergistic targets.
In 2015,MedtronicReceivePurchasing Covidien has propelled Medtronic to become the world's largest medical device company. The neurointerventional product line, inherited from ev3, has now become one of Medtronic’s leading businesses, covering both hemorrhagic and ischemic conditions. StrykerMore than 6 M&A deals in 2024Approximately 16.25% of the market share, becomingThe second largest after MedtronicGodVia interventional enterprises, throughTechnological integration has an absolute advantage in the high-end product field (such as dense mesh stents, next-generation thrombectomy stents). Johnson & JohnsonRelying on Cerenovus andCodman Neuro, Two Core Brands at the Forefront of the Global Neurointerventional Device Market. In 2024, Johnson & Johnson's cardiovascular business revenue reached $7.707 billion, a significant year-over-year increase of 21.4%. The innovation and market penetration of neurovascular-related products were among the key growth drivers.
Now the acquisition case has been officially announced.，Instructions perhaps earlier BossDun Science has already started to get in touchPenumbra。
This acquisition marksBoston Scientific Returns to the Neurovascular Track，The deal was reached at $374 per share, aPenumbraLast Closing PricePremium of 19.3%, Showed Boston Scientific's Determination to Acquire。After the acquisition is completed, in the competition with Johnson & Johnson and Medtronic in the interventional track,Having More Initiative。
First, the scarcity of targets。
Good targets for cardiovascular newcomers have almost been bought out by the leading cardiovascular giants. Previously, the top five cardiovascular newcomersRui ZhongAbiomed (Heart Pump)、Penumbra (Neurointervention)、Shockwave (Balloon)、Inari (Peripheral Thrombectomy)、Farapulse（PFA），Besides Penumbra, four of which have been acquired currently.。
PenumbraIt is one of the best cardiovascular targets on the market currently.
In terms of business, on the one hand, Penumbra, founded in 2004, focuses on the field of neurovascular intervention.Highly aligned with Boston Scientific's requirements in the business field。
Neurointervention Product Line: Penumbra's neurovascular products currently include differentiated solutions for access, stroke revascularization, and neuroembolization.
On the other hand, Stryker's acquisition of Inari Medical in early 2025, betting on the signals of peripheral thrombosis and pulmonary embolism, has also drawn significant attention from leading cardiovascular companies in the field.Market Space and Growth Potential in Areas Such as Peripheral Thrombosis, Pulmonary Embolism, and Mechanical Thrombectomy Are Being Re-evaluatedPenumbra's products in the embolization field can also strengthen Boston Scientific's layout in this area.
BTIG Analyst Ryan ZimmermanIt was pointed out that "Penumbra, as a merger and acquisition target that has been receiving attention from several giants in recent years, its technological advantages and market position were highlighted when Stryker acquired it last year.Inari Medical"Even more prominent later."
Peripheral Product Line: Penumbra offers innovative mechanical thrombectomy products for peripheral vascular procedures to remove blood clots that cause blockages in arteries, veins, and pulmonary vessels, including the Lightning Bolt and Lightning Flash computer-assisted vacuum thrombectomy systems.
Secondly, the revenue data is positive, and the market highly recognizes it.
On the same day Penumbra was officially announced to be acquired, the company also disclosed its unaudited preliminary financial data for the fourth quarter and full year of 2025.Demonstrate strong growth momentum.
In the fourth quarter of 2025, Penumbra's revenue ranged between $383 million and $384.8 million, a year-on-yearIncrease by 21.4% to 22%Excluding the impact of the China region, the revenue growth rate reached as high as 23.2% to 23.8%; the full-year revenue was $1.4013 billion to $1.4031 billion, a year-on-yearIncrease by 17.3% to 17.5%, excluding the China region, the growth rate increased to 24.7% to 24.9%.
In addition, after the acquisition news was released,PenumbraStock Price on the DaySoar12%To352.05USD, ReflectHigh market recognition of transactions。
